Zusammenfassung
Die Therapie und die Prognase bösartiger Tumoren der hängen entscheidend von
-
der Tumorgröße,
-
dem Tumorstadium und
-
der histopatholosgischen Charakterisierung zum Zeitpunkt der Diagnosestellung ab.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abeloff MD, Eggleston JC, Mendelsohn G, Ettinger DS, Baylin SB (1979) Changes in morphologie and biochemical characteristics of small cell carcinoma of the lung. Am J Med 66:757–764
Ahrendt SA, Chow JT, Yang SC et al. (2000) Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 60:3155–3159
Albelda SM, Wiewrodt R, Zuckerman JB (2000) Gene therapy for lung disease: hype or hope? Ann Intern Med 132:649–660
Albrechtsen N, Dornreiter I, Grosse F, Kim E, Wiesmüller L, Deppert W (1999) Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 18:7706–7717
Antonia SJ, Sotomayor E (2000) Gene therapy for lung cancer. Curr Opin Oncol 12:138–142
Baker SJ, Fearon ER, Nigro JM et al. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221
Bartsch H, Hollstein M, Mustonen R et al. (1995) Screening for putative radon-specific p53 mutation hotspot in German uranium miners. Lancet 346:121
Baselga J (1999) New horizons: gene therapy for cancer. Anticancer Drugs [Suppl 1] 10:S39–S42
Bates S, Vousden K (1999) Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55:28–37
Benezra JM, Kornstein MJ, Grimes MM, Krystal G (1994) Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145:1036–1040
Bennett WP, Colby TV, Travis WD et al. (1993) p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53:4817–4822
Betz E, Papadopoulos T, Buchwald J, Dämmrich JR, MüllerHermelink HK (1995) Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarein omas and other non small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. Cancer Res 55:4283–4286
Biome O (1993) Geschichte, Ursachen und Verlaufs schilderung der “Schneeberger Lungenkrankheit” bzw. der Berufskrankheit Nr. 92 der ehemaligen Deutschen Demokratischen Republik/Nr. 2402 der Bundesrepublik Deutschland. BG 104:38–46
Brennan J, O’Connor T, Makuch RW et al. (1991) Myc family amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimes. Cancer Res 51: 1708–1712
Bülzebruck H, Drings P (1991) Classification of lung cancer: first experiences with the new TNM-dassification (4th edn). Eur Respir J 4:1197–2206
Bülzebruck H, Bopp R, Drings P et al. (1992) New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM dassification. Cancer 70:1102–1110
Bunn PA, Soriano A, Helfrich BA et al. (2000) Her2/neu expression and effects of herceptin alone and in combination with cytotoxic agents in lung cancer. Proc Am Assoc Cancer Res 41:719
Butz M (1999) Beruflich verursachte Krebserkrankungen-Eine Darstellung der im Zeitraum 1978 bis 1997 anerkannten Fälle. Hauptverband der gewerblichen Berufsgenossenschaften, Sankt Augustin
Carbone DP (1997) The biology of the lung cancer. Semin Oncol 24:388–401
Carbone DP (1999) Molecular modalities in the treatment of lung cancer. Oncology [Suppl 5] 13:142–147
Chan DC, Soriano A, Kane MA, Helfrich B, Bunn PA (2000) Biology of lung cancer. In: Hansen H (ed) The IASLC textbook of lung cancer. Dunitz, London, pp 27–73
Chiba I, Takahashi T, Nau MM et al. (1990) Mutations in the p53 gene are frequent in primary, resected non small lung cancer. Oncogene 5:1603–1606.
Chin K, Ueda K, Pastan I, Gottesman M (1992) Modulation of activity of the promotor of the human MDRI gene by ras and p53. Science 255:459–462
Chiu R, Boyle WJ, Meek J, Hunter T, Karin M (1988) The c-fos protein interacts with c-jun/AP-1 to stimulate transcription from AP-l responsive genes. Cell 54:541–542
Chung GTY, Sundaresan V, Hasleton P, Rudd R, Taylor R, Rabbitts PH (1996) Clonal evolution of lung tumors. Cancer Res 56:1609–1614
Dalquen P, Sauter G, Torhorst J et al. (1996) Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 178:53–58
Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY (1999) DNA damage-induced cell cyde checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18:7883–7899
De Jong D, Prins FA, Mason DY, Reed JC, Van Ommen GB, Kluin PM (1994) Subcellular localization of the bd-2 protein in malignant and normal lymphoid cells. Cancer Res 54:256–260
Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274:430–432
DePinhoo RA, Schreiber-Agus N, Alt FW (1991) Myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 57:1–46
De Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK, Koeffler HP (1995) Alterations of CDKN2 (p16) in non-small celling cancer. Genes Chromosomes Cancer 14:164–170
Disis ML, Cheever MA (1997) HER-2/neu protein: a target for antigen-specific immuntherapy of human cancer. Adv Cancer Res 71:343–371
Dockhorn-Dworniczak B, Simon R, Brinkschmidt C, Poremba C, Böcker W (1998) Molekularbiologic maligner Tumorerkrankungen. Onkologe 4:671–681
Dosaka-Akita H, Hu SX, Fujino M et al. (1997) Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 79:1329–1337
Drings P (1993) Diagnostics and staging as a basis for planning therapy in lung cancer. Gen Thorac Surg 14–24
Ebina M, Steinberg SM, Mulshine JL, Linnoila RI (1994) Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496–2503
El-Deiry WS, Tokino T, Velculescu VE et al. (1993) WAFI a potential mediator of p53 tumor suppression. Cell 75:817–825
Fidler IJ (1997) Molecular biology of cancer: invasion and metastasis. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott-Raven, Philadelphia, pp 135–152
Fields S, Jang S (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046–1049
Fisseler-Eckhoff A, Müller K-M (1992) Early cancer and preneoplastic lesions of the lung-extracellular matrix components. In: Bernal SD, Hesketh PJ (eds) Lung cancer differentiation. Implications for diagnosis and treatment. Dekker, New York, pp 78–89
Fisseler-Eckhoff A, Müller K-M (1994) Pathologic der Pulmonalarterien bei Lungentumoren. Dtsch Med Wochenschr119:1415–1420
Fong KM, Sekido Y, Minna JD (1999) Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 118:1136–1152
Fontanini G, Bigini D, Vignati S et al. (1995a) Microvessel count predicts metastatic disease and survival in nonsmall cell lung cancer. J Pathol 177:57–63
Fontanini G, Vignati S, Bigini D et al. (1995b) Bd-2 protein: a prognostic factor inversely correlated to p53 in nonsmall-cell lung cancer. Br J Cancer 71:1003–1007
Frederiksen KS, Petri A, Abrahamsen N, Poulsen HS (1999) Gene therapy for lung cancer. Lung Cancer 23:191–207
Freedman DA, Levine AJ (1999) Regulation of the p53 protein by the MDM2 oncoprotein-Thirtyeight G. H. A. Clowes Memorial Award Lecture. Cancer Res 59:1–7
Friend SH, Bernards R, Rogelj S et al. (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–645
Garziano SL, Cowan BY, Carney DN et al. (1987) Small cell lung cancer line derived from a primary tumor with a characteristic deletion of 3p. Cancer Res 48:2141–2155
Gazdar AF (1994) The molecular and cellular basis of human lung cancer. Anticancer Res 14:261–267
Gazdar AF, Carney DN, Nau MM, Minna JD (1985) Characterization of variant subdasses of cell line derived from small cell lung cancer having distinct biochemical, morphological and growth properties. Cancer Res 45:2924–2930
Geddes DM (1979) The natural history of lung cancer: a review based on rates of tumor growth. Br J Dis Chest 73:1–17
Giaccone G (1996) Oncogenes and antioncogenes in lung tumorigenesis. Chest 109:130S–134S
Gonzales S, Basewitz DB von, Grundmann E, Nakhosteen JA, Müller K-M (1986) The ultrastructural heterogeneity of potentially preneoplastic lesions in the human bronchial mucosa. Pathol Res Pract 181:408–417
Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878
Griffin CA, Baylin SB (1985) Expression of the c-myb oncogene in human small cell lung carcinoma. Cancer Res 45:272–275
Hajj C, Akoum R, Bradley E, Paquin F, Ayoub J (1990) DNA alterations at proto oncogene loci and their clinical significance in operable non small cell lung cancer. Cancer 66:733–739
Harbour JW, Lai SI, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ (1988) Abnormalities in structure and expression of the retinoblastoma gene in SCLC. Science 241:353–357
Hasimoto T, Tokuchi Y, Hayashi M et al. (1999) p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 59:5572–5577
Haugen A (2000) Etiology of lung cancer. In: Hansen H (ed) The IASLC textbook of lung cancer. Dunitz, London, pp 1–12
Hermanek P, Hutter RVP, Sobin LH, Wittekind C (1999) Classification of isolated tumor cells and micrometastasis. Cancer 86:2668–2673
Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R (1994) Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. Oncology 51:544–551
Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R (1995) High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res 15:503–505
Higashiyama M, Doi O, Kodama K et al. (1997) MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 75:1302–1308
Hirsch FR, Matthews MI, Aisner S et al. (1988) Histopathologic classification of small cell lung cancer.Changing concepts and terminology. Cancer 62:973–977
Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane proteine that blocks programmed cell death. Nature 348:334–336
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancer. Science 253:362–366
Hollstein M, Shomer B, Greenblatt M et al. (1996) Somatic point mutations in the p53 gene of human tumors and cell lines. Updated compilation. Nucleic Acids Res 24:141–146
Hollstein M, Bartsch H, Wesch H et al. (1997a) p53 gene mutation analysis in tumors of patients exposed to a-particles. Carcinogenesis 18:511–516
Hollstein M, Soussi T, Thomas G, Brevern M-C von, Bartsch H (1997b) P53 gene alterations in human tumors: perspectives for cancer control. Rec Results Cancer Res 143:370–389
Horio Y, Takahashi,Kuroishi T et al. (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53:1–4
Horowitz JM, Park SH, Bogenmann E et al. (1990) Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775–2779
Höfler H (1997) Spektrum neuro endokriner Tumoren der Lunge. Pathologe 18:322–323
Husgafvel-Pursiainen K, Hackman P, Ridanpaa M et al. (1993) K-ras mutations in human adenocarcinoma of the lung-association with smoking and occupational exposure to asbestos. Int J Cancer 53:250–256
Hussain SP, Harris CC (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58:4023–4037
Iggo R, Gatter K, Bartek J, Lane DP, Harris AL (1990) Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 355:675–679
Janus F, Albrechtsen N, Dornreiter I, Wies müller L, Grosse F, Deppert W (1999) The dual role model for p53 in maintaining genomie integrity. Cell Mol Life Sci 55:12–27
Johnson B, Ihde D, Makuch RW et al. (1987) Myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 79:1629–1634
Junker K, Müller K-M (1989) Metastasierungsmuster beim Bronchialkarzinom. Z Herz Thorax Gefäßchir 3:189–194
Junker K, Krapp D, Müller K-M (1995) Kleinzelliges Bronchialkarzinom nach ChemoTherapic. Pathologe 16:217–222
Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller K-M (1997a) Tumor regression in non-small cell lung cancer following neoadjuvant therapy-histological assessment. J Cancer Res Clin Oncol 123:469–477
Junker K, Thomas M, Schulmann K, Klinke V, Bosse U, Müller K-M (1997b) Regressionsgrading neoadjuvant behandelter niehtkleinzelliger Lungentumoren. Pathologe 18: 131–140
Kamp A, Gruis NA, Weaver-Feldhaus J et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440
Kaufmann O, Dietel M (2000) Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 36:8–16
Kern JA, Torney L, Nordberg JE, Weiner DB, Greene MI, Robinson RA (1990) p185neu expression in lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184–5191
Kern JA, Robinson RA, Gazdar A, Torney L, Weiner DB (1992) Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. Am J Respir Cell Mol Biol 6:359–363
Kiefer PE, Bepler G, Kubasch M, Havemann K (1987) Amplification and expression of protooncogenes in human small cell lung cancer cell lines. Cancer Res 47:6236–6242
Kikuchi M (1999) Retropharyngeal rhabdomyosarcoma mimicking pseudotumor cerebri. Pediatr Neurol 21:496–499
Knudson AG JR (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823
Koechli OR, Schaer GN, Scifert B et al. (1994) Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344: 1647–1648
Kok K, Osinga J, Carritt B et al. (1987) Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330:578–581
Krajewski S, Tanaka S, Takayama S, Schibier M, Fenton W, Reed JC (1993) Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmatic reticulum, and outer mitochondrial membrane. Cancer Res 53:4701–47l4
Kreuzer M, Kreienbrock L, Gerken M et al. (1998) Risk factors for lung cancer in young adults. Am J Epidemiol 147:1028–1037
Kreuzer M, Müller K-M, Gerken M, Wiehmann H-E (1999) Lung cancer histologie types and age of onset. Cancer 85: 1958–1965
Kwiatkowski DJ, Harpole DH, Godleski J et al. (1998) Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients. J Clin Oncol 16:2468–2477
Lakin ND, Jackson SP (1999) Regulation of p53 in response to DNA damage. Oncogene 18:7644–7655
Leach FS, Tokino T, Meltzer P et al. (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231–2234
Lee W, Mitchell P, Tjian R (1987) Purified transcription factor AP-l interacts with TPA-indueible elements. Cell 49:741–752
Levine AJ, Chang AW, Dittmer D et al. (1994a) The p53 tumor suppressor gene. J Lab Clin Med 123:817–823
Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M (1994b) The 1993 Walter Hubert Lecture-the role of the p53 tumour suppressor gene in tumorigenesis. Br J Cancer 69:409–416
Lichtenstein P, Holm NV, Verkasalo PK et al. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85
Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD (1983) Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306:194–196
Lotem J, Sachs L (1993) Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and differentiation-defective myeloid leukemic cells. Cell Growth Differ 4:41–47
Lubin R, Zalcman G, Bouchet L et al. (1995) Serum p53 antibodies as early markers of lung cancer. Nat Med1:701–702
Mannino DM, Ford E, Giovanni GA, Thun M (1998) Lung cancer deaths in the United States from 1979 to 1992: an analysis using multiple-cause mortality data. Int J Epidemiol 27:159–166
Marchetti A, Doglioni C, Barbareschi M et al. (1996) p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and associatiOn with tumoral differentiation. Oncogene 12:1319–1324
May P, May E (1999) Twenty years of p53 research: structural and functional aspects of the p53 protein [published erratum appears in Oncogene 2000 23:1734]. Oncogene 18:7621–7636
McDowell EM (1987) Bronchogenie carcinomas. In: McDoweil EM (ed) Current problems in tumor pathology, lung carcinomas. Churchill Livingstone, Harlow, pp 255–285
McLaren R, Kuzu I, Dunnill M, Harris CC, Lane DP, Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735–738
Mitsudomi T, Viallet J, Mulshine J, Linnoila R, Minna JD, Gazdar AF (1991) Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6: 1353–1362
Miwa W, Yasuda J, Yashima K, Makino R, Sekiya T (1994) Absence of activating mutations of the rRAF1 protooncogene in human lung cancer. Biol Chem 375:705–709
Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299
Miyashita T, Krajewski S, Krajewska M, Reed J (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799–1805
Momand J, Zambetti G, Olson D, Levine A (1992) The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237–1245
Mountain CF (1986) A new international staging-system for lung cancer. Chest [Suppl] 98:225–232
Mountain CF (1996) Lung cancer staging: 1997 revisions. In: Antypas G (ed) 2nd International Congress on Lung Cancer. Monduzzi, Bologna, pp 11–13
Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111: 1710–1717
Müller K-M (1988) Early cancer of the lung. Recent Results Cancer Res 106:119–130
Müller K-M (1999) Neues zur Pathologie der Lungentumoren. Verh Dtsch Ges Pathol 83:168–183
Müller K-M, Fisseler-Eckhoff A (1998) Pathologie der Lungentumoren. In: Drings P, Vogt-Moykopf I (Hrsg) Thoraxtumoren: Diagnostik-Staging-gegenwärtiges Therapickonzept, 2. Aufl. Springer, Berlin Heidelberg New York, S 3–34
Müller K-M, Menne R (1985) Small cell carcinoma of the lung: pathological anatomy. Recent Results Cancer Res 97:11–24
Müller K-M, Brämer UG, Hiddemann W (1986) Probleme der morphologischen Klassifikation bösartiger Lungentumoren. Atemw Lungenkrkh 12:459–465
Müller K-M, Fisseler-Eckhoff A, Reitemeyer E (1988) Stromareaktionen in Lungentumoren-Tumorvernarbung und sogenanntes Narbenkarzinom. Fortsehr Med 106:19–24
Müller K-M, Junker K, Stief A (1993) Wert und Bedeutung pathologisch-anatomischer Befunde für die Thoraxchirurgie. In: Vogt-Moykopf I, Drings P (Hrsg) Thoraxchirurgie-Stand und Ausbliek. Steinkopff, Darmstadt, S 23–35
Müller K-M, Junker K, Wiethege Th (1995) Niehtkleinzellige Lungentumoren-Morphologie, Tumorregression, Molekularpathologie. Onkologe 1:429–440
Müller K-M, Wiethege Th, Junker K (1998) Pathologie kleinzelliger Lungentumoren. Onkologe 4:996–1004
Noble J, Willetts K, Mercer W, Reddel R (1992) Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp Cell Res 203:297–304
Nobori T, Miura K, Wu D, Carson D (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–756
Nuorva K, Soini Y, Kamel D et al. (1993) Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol 142:725–732
Ohsaki Y, Toyoshima E, Fujiuchi S et al. (1996) Bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res 2:915–920
Okamoto A, Hussain SP, Hagiwara K et al. (1995) Mutations in the p16(INK4)/MTS1/CDKN2, pI5(INK4B)/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448–1451
Oren M, Rotter V (1999) p53-the first twenty years. Cell Mol Life Sci 55:9–11
Pantel K, Knebel-Boeberitz MV, Izbicki JR, Riethmüller G (1997) Disseminierte Tumorzellen: Diagnostik, prognostische Relevanz, Phänotypisierung und therapeutische Strategien. Chirurg 67:1241–1250
Pappai G, Pöhl CD (1999) Uranerzbergbau und Berufsgenossenschaften: Das Berufskrankheitengeschehen der ehemaligen Wismut-Beschäftigten. BG 110:596–602
Petersen I, Langreck H, Wolf G et al. (1996) Small cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 1Oq, 13q, and 17p. Br J Cancer 75:79–86
Petersen I, Bujard M, Petersen S et al. (1997) Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 57:2331–2335
Petit AM, Rak J, Hung MC et al. (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523–1530
Pezzella F, Turley H, Kuzu I et al. (1993) Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690–694
Pohlabeln H, Jöckel K, Müller K-M (1997) The relation between various histological types of lung cancer and the number of years since cessation of smoking. Lung Cancer 18:223–229
Quinlan DC, Davidson A, Summers C, Warden H, Doshi H (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828–4831
Quintinilla M, Bron K, Ramsden N, Balmain A (1986) Carcinogen-specific mutation and amplification of H-ras during mouse skin carcinogenesis. Nature 322:78–80
Rachwal WJ, Bongiorno PF, Orringer MB, Whyte RI, Ethier SP, Beer DG (1995) Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 72:56–64
Rak J, Mitsuhashi Y, Bayko L et al. (1995) Mutant ras oncogenes upregulate VEGFJVPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575–4580
Ransonne LJ, Verma IM (1990) Nuclear oncogenes fos and jun. Annu Rev Cell Biol 6:539–557
Raycroft L, Wu HY, Lozano G (1990) Transcriptional activation by wild type but not transforming mutants of the p53 anti oncogene. Science 249:1049–1051
Reissmann PT, Koga H, Takahashi R et al. (1993) Inactivation of the retinoblastoma susceptibility gene in nonsmall-cell lung cancer. The Lung Cancer Study Group. Oncogene 8:1913–1919
Rodenhuis S, Van de Wetering ML, Mooi WJ, Evers S, Zandwijk N van, Bos JL (1987) Mutational activation of the kras oncogene: a possible pathogenic factor in adenocarcinoma of the lung. N Engl J Med 317:929–935
Rodenhuis S, Siebos RJC, Boot AJ et al. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48:5738–5741
Rosell R, Gomez-Codina J, Camps C et al. (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153–158
Roth JA (1995) Molecular events in lung cancer. Lung Cancer 12:S3–S15
Roth JA, Fossella F, Komaki R et al. (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Nat Cancer Inst 86:673–680
Rusch V, Klimstra D, Venkatraman E et al. (1995) Aberrant p53 expression predicts clinical resistance to cisplatinbased chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038–5042
Rygaard K, Nakamura T, Sang-Thomsen M (1993) Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stern cell factor, in SCLC cell lines and xenografts. Br J Cancer 67:37–46
Schirren CI (1996) Die systematische mediastinale Lymphknotendissektion beim Bronchialkarzinom-Indikation, Technik und Ergebnisse. Habilitationsschrift, RuprechtKarl-Universität Heidelberg
Schmitz I, Fisseler-Eckhoff A, Erfkamp S, Twent U, Müller K-M, Becker H (1994) Characterization of cytokeratin expression in squamous cell carcinoma of the lung-immunohistochemical and electronmicroscopical investigations. In: Antypas G (ed) International Congress for Lung Cancer. Monduzzi, Bologna, S 123–127
Schraufnagel DE (1990) Electron microscopy of the lung. Dekker, New York
Schuette J, Nau M, Birrer M, Thomas F, Gazdar AF, Minna JD (1988) Constitutive expression of multiple mRNA forms of the c-jun oncogene in human lung cancer cell lines. Proc Am Assoc Cancer Res 29:455
Sekido Y, Obata Y, Ueda R et al. (1991) Preferential expression of c-kit protooncogene transscripts in small cell lung cancer. Cancer Res 51:2416–2419
Selter H, Montenarh M (1994) The emerging picture of p53. Int Arch Occup Environ Health 26:145–154
Selter H, Amela-Neuschwander S, Villena-Heinsen C, Montenarh M (1995) Antibodies against murine double minute-2 (mdm2) in sera of patients with various gynaecological diseases. Cancer Lett 96: 111–115
Shapiro GI, Edward CD, Kobzik L et al. (1995) Reciprocal Rb inactivation and p16(INK4) expression in primary lung cancers and cell lines. Cancer Res 55:505–509
Shew JY, Chen PL, Bookstein R, Lee EY (1990) Deletion of a splice donor site ablates expression of the following exons and produces an unphosphorylated RB protein unable to bind SV40 T antigen. Cell Growth Differ 1:17–25
Shimizu E, Coxon A, Otterson GA et al. (1994) RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9:2441–2448
Shows TB, McAlpine PJ, Boucher C et al. (1987) Guidelines for human gene nomenclature. An international system for human gene nomenclature (ISGN, 1987). Cytogenet Cell Genet 46:11–28
Siegfried JM, Davis AJ, Gubish CT et al. (1998) Growth factors and recepetors in non-small cell lung cancer. In: Kane MA, Bunn PA (eds) Biology of lung cancer. Dekker, New York, S 317–336
Slamon DJ, Godolphin W, Jones LA et al. (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707–712
Slamon DJ, Leyland-Jones B, Shak S et al. (1998) Addition of herceptin (humanized anti Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases antieancer activity: a randomized multinational controlled phase III trials. Proc Am Soc Clin Onco117:98a
Siebos RJ, Kibbelaar RE, Dalesio O et al. (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561–565
Soini Y, Kamel D, Nuorva K, Lane DP, Vähäkangas K, Pääkko P (1992) Low p53 protein expression in salivary gland tumours compared with lung carcinomas. Virchows Arch 421:415–420
Soussi T (2000) p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777–1788
Sozzi G, Veronese ML, Negrini M et al. (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85:17–26
Sugio K, Kishimoto Y, Virmani AK, Hung JY, Gazdar AF (1994) K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 54:5811–5815
Szabo E, Riffe ME, Steinberg SM, Birrer MJ, Linnoila RI (1996) Altered cJUN expression: an early event in human lung careinogenesis. Cancer Res 56:305–315
Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M (1994) P53 mutation hotspot in radon-associated lung cancer. Lancet 343:86–87
Thomas M, Rübe C, Semik M et al. (1999) Impact of preoperative bimodality induction including twice-daily-radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 17:1185–1193
Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD (1997) p53-dependent regulation of MDRI gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 94:11037–11042
Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, collaborators from 14 countries (1999) histological typing of lung and pleural tumors, 3rd edn. Springer, Berlin Heidelberg New York
True LD (1990) Atlas of diagnostic immunohistopathology. Lippincott, Philadelphia
Tseng JE, Rodriguez M, Ro J, Liu D, Hong WK, Mao L (1999) Gender differences in pS3 mutational status in small cell lung cancer. Cancer Res 59:5666–5670
Tsujimoto Y, Cossman J, Jaffe E, Croce CM (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440–1443
Vähäkangas KH, Samet JM, Lane DP, Harris CC et al. (1992) Mutations of p53 and ras gene in radon associated lung cancer from uranium miners. Lancet 339:576–580
Volm M, Efferth T, Mattem J (1992) Oncoprotein (c-myc, cerbB1, c-erbB2, c-fos) and suppressor gene products (p53) gene expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 12:11–20
Volm M, Drings P, Mattem J, Wodrieh W (1993a) Prognostic value of oncoproteins for the survival of patients with non-small cell lung carcinomas. Int J Cancer 2:767–772
Volm M, Drings P, Wodrieh W (1993b) prognostic significance of the expression of c-fos, c-jun and erbB-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 119:507–510
Volm M, Vogt-Moykopf I, Wodrieh W (1993c) C-K-ras and c-N-ras are important and stage-independent prognostic indicators in adenocarcinomas of the lung. Cancer J Sci Am 6:37–42
Walker C, Robertson L, Myskow M, Dixon G (1995) Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer72:164–169
Wallace-Brodeur RR, Lowe SW (1999) Clinical implications of p53 mutations. Cell Mol Life Sci 55:64–75
Weidner N (1995) Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9–19
Wen D, Peles E, Cuppies R et al. (1992) Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin ho molo gy unit. Cell 69:559–572
Whang-Peng J, Kao-Shan CS, Lee EC et al. (1982) Specific chromosome defects associated with human small-cell lung cancer; deletion 3p(14-23). Science 215:181–182
Wiethege Th, Voss B, Müller K-M (1994) Immunhistochemische Untersuchungen zur Akkumulation des TumorSuppressor-Gens p53 in Bronchialkarzinomen. Atemw Lungenkrkh 20:326–328
World Health Organization (1981) International histological classification of tumours No. 1, 2nd edn. World Health Organization, Geneva
World Health Organization (1982) The World Health Organization histologic al typing of lung tumours-2nd edn.Am J Clin Pathol 77:123–136
Wu GS, Eldeiry WS (1996) P53 and chemosensitivity. Nat Med 2:255–256
Xiao S, Li D, Corson J, Vijg J, Fleteher JA (1995) Codeletion of pl5 and pl6 genes in primary non-small cell lung cancer. Cancer Res 55:2968–2971
Xu H, Cagle P, Hu S et al. (1995) Altered retinoblastoma (RB) and p53 protein status as a synergistie prognostic factor in non-small cell lung carcinoma. Proc Am Assoc Cancer Res 36:246
Yang Q, Wesch H, Müller K-M, Bartsch H, Wegener K, Hollstein M (1999) Analysis of radon-associated squamous cell carcinomas of the lung for a p53 gene hot spot mutation. Br J Cancer 82:763–766
Yap DB, Hsieh JK, Chan FS, Lu X (1999) mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18:7681–7689
Yokota J, Wada M, Shimosato Y, Terada M, Sugimura T (1987) Loss of heterozygosity on chromosomes 3, 13, and 17 in small ceH carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 84:9252–9256
Yokota J, Shimosato Y, Sugimura T, Terada M (1988) Altered expression of the retinoblastoma (RB) gene in small cell carcinoma of the lung. Oncogene 3:471–475
You H, Candrian U, Maronpot RR, Stoner GD, Anderson MW (2000) Activation of Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of strain A mouse. Proc Natl Acad Sci USA 86:3070–3074
Zangemeister-Wittke U, Stahel RA (1999) Novel approaches to the treatment of small-cell lung cancer. Cell Mol Life Sci 55:1585–1598
Babcock TL, Powell DH, Bothwell RS (1976) Radiation-induced peritoneal mesothelioma. J Surg Oncol 8:369–372
Balsara BR, Bell DW, Sonoda G et al. (1999) Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q 11.1-15 in human malignant mesothelioma. Cancer Res 59:450–454
Baris I, Artvinli M, Sahin AA (1979) Environmental mesothelioma in Turkey. Ann N Y Acad Sci 330:432
Baris I, Simonato L, Artvinli M et al. (1987) Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study of the Cappadoeian region of Turkey. Int J Cancer 39:10–17
Battifora H, McCaughey WTE (1995) Tumors of the serosal membran es, 3rd edn. Armed Forces Institute of Pathology, Washington, DC
Beer TW, Buchanan R, Matthews AW, Stradling R, Pullinger N, Pethybridge RJ (1998) Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype. Hum Pathol 29:246–251
Bell DW, Jhanwar SC, Testa JR (1997) Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 57:4057–4062
Berman JJ, Rice JM (1979) Mesotheliomas and proliferative lesions of the testicular mesothelium in Fischer, SpragueDawley and Buffalo rats by methyl(acetoxymethyl)-nitrosamine (DMN-OAc). Vet Pathol 16:574–582
Bermudez E, Everitt J, Walker C (1990) Expression of growth factor and growth factor receptor RNA in rat pleural mesothelial cells in culture. Exp Cell Res 190:91–98
Bianchi C, Brollo A, Zuch C (1993) Asbestos-related familial mesothelioma. Eur J Cancer Prev 2:247–250
Bianchi AB, Mitsunaga SI, Cheng JQ et al. (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854–10858
Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S (1997) Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 75:523–527
Bjorkqvist AM, Tammilehto L, Nordling S et al. (1998) Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 77:260–269
Bjorkqvist AM, Wolf M, Nordling S et al. (1999) Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer 81:1111–1115
Bonn D (1999) Mesothelioma deaths may double within 20 years. Lancet 353:383
Boutin C, Rey F, Viallat JR (1995) Prevention of malignant see ding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 108:754–758
Brenner J, Sordillo PP, Magill GB, Golbey RB (1982) Malignant mesothelioma of the pleura: review of 123 patients. Cancer 49:2431–2435
Brinkmann OA, Müller KM (1989) What’s new in intraperitoneal test on Kevlar (asbestos substitute)? Pathol Res Pract 185:412–417
Brown JW, Kristensen KAB, Monroe LS (1968) Peritoneal mesothelioma following pneumoperitoneum maintained for twelve years: report of a case. Am J Dig Dis 13:830–835
Bültzingslöwen F von, Siernon G (1999) Die Therapic des malignen Pleuramesothelioms-ein fortdauerndes Dilemma. Pneumologie 53:266–275
Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robinson BW, Scott B (1999) Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12. Am J Respir Cell Mol Biol 21:347–356
Carbone M, Pass HI, Rizzo P et al. (1994) Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9: 1781–1790
Carbone M, Rizzo P, Grimley PM et al. (1997a) Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 3:908–912
Carbone M, Rizzo P, Pass HI (1997b) Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 15:1877–1888
Center R, Lukeis R, Dietzsch E, Gillespie M, Garson OM (1993) Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma. Genes Chromosomes Cancer 7:47–53
Cheng JQ, Jhanwar SC, Lu YY, Testa JR (1993) Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 53:4761–4763
Cheng JQ, Jhanwar SC, Klein WM et al. (1994) p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547–5551
Cicala C, Pompetti F, Nguyen P, Dixon K, Levine AS, Carbone M (1992) SV40 small t deletion mutants preferentially transform mononueIear phagocytes and B lymphocytes in vivo. Virology 190:475–479
Cicala C, Pompetti F, Carbone M (1993) SV40 induces mesotheliomas in hamsters. Am J Pathol 142:1524–1533
Cristaudo A, Vivaldi A, Sensales G et al. (1995) Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40. J Environ Pathol Toxicol Oncol 14:29–34
Dawson A, Gibbs A, Browne K, Pooley F, Griffiths M (1992) Familial mesothelioma. Details of 17 cases with histopathologic findings and mineral analysis. Cancer 70: 1183–1187
De Luca A, Baldi A, Esposito V et al. (1997) The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 3:913–916
Donna A, Betta PG (1982) Mesodermomas: a new embryological approach to primary tumours of coelomic surfaces. Histopathology 5:31–44
Donna A, Betta PG (1986) Differentiation towards cartilage and bone in a primary tumour of pleura. Further evidence in support of the concept of “mesodermoma”. Histopathology 10:101–108
Donna A, Betta PG, Bianchi V et al. (1991) A new insight into the histogenesis of “mesodermomas”-malignant mesotheliomas. Histopathology 19:239–244
Elmes PC, Simpson JC (1976) The clinical aspects of mesothelioma. QJM 45:427–429
Fitzpatrick DR, Bielefeldt-Ohmann H, Himheck RP, Jarnicki AG, Marzo AL, Robinson BW (1994) Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 11:29–44
Flejter WL, Li FP, Antman KH, Testa JR (1989) Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes.Genes Chromosomes Cancer 1:148–154
Frizelle SP, Grim J, Zhou J et al. (1998) Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 16:3087–3095
Gilks B, Hegedus C, Freeman H, Fratkin L, Churg A (1988) Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer 61:2019–2021
Gillissen A, Wiethege T (1996) Zelluläre Reaktionen der Lunge auf Mineralfasern. Pneumologie 50:5–17
Hagemeijer A, Versnel MA, Van Drunen E et al. (1990) Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 47:1–28
Hammar SP, Bolen JW (1988) Pleural neoplasms. In: Dail DH, Hammar SP (eds) Pulmonary pathology, 1st edn. Springer, Berlin Heidelberg New York, pp 973–1028
Hammond EC, Selikoff IJ, Churg J (1965) Neoplasia among insulation workers in the United States with special reference to intra-abdominal neoplasia. Ann N Y Acad Sci 132:519–525
Hammond EC, Selikoff IJ Scidman H (1970) Asbestos exposure, cigarette smoking and death rates. Ann N Y Acad Sci 330:473–490
Harington JS, McGlashan ND (1998) South African asbestos: production, exports, and destinations, 1959-1993. Am J Ind Med 33:321–326
Harvey P, Warn A, Dobbin S et al. (1998) Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology. Br J Cancer 77:1052–1059
Heineman EF, Bernstein L, Stark AD, Spirtas R (1996) Mesothelioma, asbestos, and reported his tory of cancer in first-degree relatives. Cancer 77:549–554
Hueper WC (1964) Cancer induction by polyurethan and polysilicone plastics. J Natl Cancer Inst 33:1005–1027
Huncharek M, Kelsey K, Muscat J, Christiani D (1996) Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study. Cancer Lett 102:205–208
Huzly A (1989) Parietale Pleurektomie bei der sekundären Pleurakarzinose. Z Herz Thorax Gefäßchir 3:80–83
Jones JS (1993) The formation and function of the mesothelioma panel of the Commission of the European Communities. Commission of the European Communities. Office for Official Publications of the European Communities, Brussels
Kallioniemi A, Kallioniemi OP, Sudar D et al. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818–821
Karakoca Y, Emri S, Cangir AK, Baris YI (1997) Environmental pleural plaques due to asbestos and fibrous zeolite exposure in Turkey. Indoor Built Environ 6:100–105
Katschinski HU, Müller KM (1994) Pleuramesotheliome im Raum Dresden 1964-1987. Arbeitsmed Sozialmed Umweltmed 7:284–288
Ke Y, Reddel RR, Gerwin BI et al. (1989) Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol l34:979–991
Kivipensas P, Bjorkqvist AM, Karhu R et al. (1996) Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 89:7–l3
Klemperer P, Rabin CB (1931) Primary neoplasms of the pleura: a report of five cases. Arch Pathol Lab Med 11:385–412
Knuutila S, Armengol G, Bjorkqvist AM et al. (1998) Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. Cancer Genet Cytogenet 100:25–30
König JE, Tolnay E, Wiethege T, Müller KM (2000) Co-Dexpression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration 67:36–40
Krismann M, Wiethege T, Müller K (1999) Calretinin and p53 as markers for differentiation between reactive and neoplastic pleuralIesions? Virchows Arch 435:287
Krismann M, Müller KM, Jaworska M, Johnen G (2000) Severe chromosomal aberrations in pleural mesotheliomas with unusual mesodermal features-comparative genomic hybridization evidence for a mesothelioma subgroup. J Mol Diag 2:209–216
Kucharczuk JC, Randazzo B, Chang MY et al. (1997) Use of a “replication-restricted” herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57:466–471
Lanuti M, Gao GP, Force SD et al. (1999) Evaluation of an EIE4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther 10:463–475
Lee WC, Testa JR (1999) Somatic genetic alterations in human malignant mesothelioma. Int J Oncol 14:181–188
Lee WC, Balsara B, Liu Z, Jhanwar SC, Testa JR (1996) Loss of heterozygosity analysis defines a critical region in chromosome Ip22 commonly deleted in human malignant mesothelioma. Cancer Res 56:4297–4301
Leers MPG, Aarts MMJ, Theunissen PHMH (1998) E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 32:209–216
Libbus BL, Craighead JE (1988) Chromosomal translocations with specific breakpoints in asbestos-induced rat mesotheliomas. Cancer Res 48:6455–6461
Lu YY, Jhanwar SC, Cheng JQ, Testa JR (1994) Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer 9:76–80
Lukacs KV, Porter CD, Pardo OE et al. (1999) In vivo transfer of bacterial marker genes results in differing levels of gene expression and tumor progression in immunocompetent and immunodeficient mice. Rum Gene Ther 10:2373–2379
Mark J (1978) Monosomy 14, monosomy 22 and 13q-three chromosomal abnormalities observed in cells of two malignant mesotheliomas studied by banding techniques. Acta Cytol 22:398–401
Martinis UJ, Radovic VR (1965) Pleural mesothelioma in a patient with pulmonary tuberculosis. Report of a case. Dis Chest 47:568–570
Marzo AL, Fitzpatrick DR, Robinson BW, Scott B (1997) Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 57:3200–3207
Matker CM, Rizzo P, Pass HI et al. (1998) The biological activities of simian virus 40 large-T antigen and its possible oncogenic effects in humans. Monaldi Arch Chest Dis 53:193–197
Maurer R, Egloff B (1975) Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 36: 1381–1385
Maximow A (1927) über das Mesothel (Deckzellen der serösen Häute) und die Zellen der serösen Exsudate. Untersuchungen an entzündetem Gewebe und an Gewebskulturen. Arch Exp Zellforsch 4: 1–42
McCaughey WT, McDonald AD (1977) Epidemiology of mesothelioma from estimated incidence. Prev Med 6:426–446
McClure HM, Graham CE (1973) Malignant uterine mesotheliomas in squirrel monkeys following diethylstilbestrol administration. Lab Anim Sci 23:493–498
McDonald JC (1985) Health implications of environmental exposure to asbestos. Environ Health Perspect 62:319–328
McDonald AD, McDonald JC (1973) Epidemiologie surveillance of mesothelioma in Canada. Can Med Assoc J 109:359–362
McDonald AD, McDonald JC (1980) Malignant mesothelioma in North America. Cancer 46:1650–1656
Meloni AM, Stephenson CF, Li FP, Sandberg AA (1992) del(6q) as a possible primary change in malignant mesothelioma [published erratum appears in Cancer Genet Cytogenet 1992 61:110]. Cancer Genet Cytogenet 59:57-61
Metcalf RA, Welsh JA, Bennett WP et al. (1992) p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 52:2610–2615
Mor O, Yaron P, Huszar M et al. (1997) Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol16:9–l3
Motherby H, Marcy T, Hecker M et al. (1998) Static DNA cytometry as a diagnostic aid in effusion cytology. 1. DNA aneuploidy for identification and differentiation of primary and secondary tumors of the serous membranes. Anal Quant Cytol Histol20:153–161
Müller KM (1997) Mesotheliome-Pathologie/Pathogenese/ Mesotheliomregister. Pneumologie 51:335–344
Mutti L, Carbone M, Giordano GG, Giordano A (1998) Simian virus 40 and human cancer. Monaldi Arch Chest Dis 53:198–201
National Institute for Occupational Safety and Health (1981) Ethylene oxide: evidence of carcinogenicity. 35. NIOSH Current Intelligence Bulletin. NIOSH, Cineinnati, OH
Om S, Odden S, Osnes M (1991) [Familial clustering of asbestos-related diseases]. Tidsskr N or Laegeforen 111: 1099–1101
Orosz Z, Nagy P, Szentirmay Z, Zalatnay A, Hauser P (1999) Epithelial mesothelioma with deciduoid features. Virchows Arch 434:263–266
Otte KE, Sigsgaard TI, Kjaerulff J (1990) [Massive exposure to asbestos and malignant mesothelioma, familial accumulation]. Ugeskr Laeger 152:3013–3014
Pass HI, Kennedy RC, Carbone M (1996) Evidence for and implications of SV 40-like sequences in human mesotheliomas. Important Adv Oncol 1996:89–108
Pepper C, Jasani B, Navabi H, Wynford-Thomas D, Gibbs AR (1996) Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Thorax 51: 1074–1076
Peterson JT, Greenberg SD, Buffler PA (1984) Non-asbestosrelated malignant mesothelioma. A review. Cancer 54:951–960
Pogrebniak HW, Lubensky IA, Pass BI (1993) Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future Therapics? Surg Oncol 2:235–240
Popescu NC, Chahinian AP, DiPaolo JA (1988) Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res 48:142–147
Prins JB, Williamson KA, Kamp MM et al. (1998) The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75:649–653
Procopio A, Strizzi L, Giuffrida A et al. (1998) Human malignant mesothelioma of the pleura: new perspectives for diagnosis and therapy. Monaldi Arch Chest Dis 53:241–243
Ribotta M, Roseo F, Salvio M et al. (1998) Recurrent chromosome 6 abnormalities in malignant mesothelioma. Monaldi Arch Chest Dis 53:228–235
Riddell RH, Goodman MJ, Moossa AR (1981) Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. Cancer 48:134–139
Risberg B, Nickels J, Wagermark J (1980) Familial clustering of malignant mesothelioma. Cancer 45:2422–2427
Rosenberg LE, Schechter A (2000) Gene therapist, heal thyself. Science 287:1757
Sanders CL, Jackson TA (1972) Induction of mesotheliomas and sarcomas from “hot spots” of 239PuO2 activity. Health Phys 22:755–759
Schoental R, Gibbard S (1972) Nasal and other tumours in rats given 3,4,5-trimethoxyeinnamaldehyde, a derivate of sinapaldehyd and of other x,b-unsaturated aldehydic wood lignin constituents. Br J Cancer 26:504–505
Schwarzenberger P, Harrison L, Weinacker A et al. (1998a) The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther 9:2641–2649
Schwarzenberger P, Harrison L, Weinacker A et al. (1998b) Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc 150:168–174
Sekido Y, Pass HI, Bader S et al. (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227–1231
Shivapurkar N, Wiethege T, Wistuba II et al. (1999) Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem 76: 181–188
Smythe WR, Hwang HC, Amin KM et al. (1994) Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 54:2055–2059
Smythe WR, Hwang HC, Elshami AA, Amin KM, Albelda SM, Kaiser LR (1995) Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. J Thorac Cardiovasc Surg 109:626–630
Solheim P, Saeter G, Finnanger AM et al. (1992) Highdose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65:956–960
Stenton SC (1997) Asbestos, Simian virus 40 and malignant mesothelioma. Thorax [Suppl 3] 52:S52–S57
Sterman DH, Kaiser LR, Albelda SM (1998a) Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 12:553–568
Sterman DH, Treat J, Litzky LA et al. (1998b) Adenovirusmediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083–1092
Stewart DJ, Gertler SZ, Tomiak A et al. (1994) High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases. Lung Cancer 11:251–258
Stock RJ, Fu YS, Carter JR (1979) Malignant peritoneal mesothelioma following radiotherapy for seminoma of the testis. Cancer 44:914–919
Tagnon I, Blot WJ, Stroube RB et al. (1980) Mesothelioma associated with the shipbuilding industry in coastal Virginia. Cancer Res 40:3875–3879
Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR (1993) Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma [published erratum appears in Cancer Res 1993 53:5063]. Cancer Res 53:4349–4355
Talerman A, Montero JR, Chilcote RR (1985) Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature. Am J Surg Pathol 9:73–80
Terao K (1978) Mesotheliomas induced by sterigmatocystin in Wistar rats. Gann 69:237–247
Tiainen M, Tammilehto L, Mattson K, Knuutila S (1988) Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet 33:251–274
Tiainen M, Tammilehto L, Rautonen J, Tuomi T, Mattson K, Knuutila S (1989) Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer 60:618–626
Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, in collaboration with LH Sobin and pathologists from 14 countries (1999) Histological classification of lung and pleural tumours, 3rd edn. Springer, Berlin Heidelberg New York
Treat J, Kaiser LR, Sterman DH et al. (1996) Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). Hum Genet Ther 7:2047–2057
Versnel MA, Claesson-Welsh L, Hammacher A et al. (1991) Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 6:2005–2011
Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17:260–271
Walker C, Rutten F, Yuan X, Pass H, Mew DM, Everitt J (1994) Wilms’ tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 54:3101–3106
Wiethege T, Philips S, Müller KM (1997) Calretinin als Marker zur Differentialdiagnose von Mesotheliomen und Adenokarzinomen. Verh Dtsch Ges Pathol 81:417
Woitowitz HJ (1987) Epidemiologie und Prävention des malignen Pleuramesothelioms. Med Klin 82:578–581
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Müller, KM., Wiethege, T., Krismann, M., Junker, K., Johnen, G. (2002). Molekulare Pathologie bösartiger pulmonaler und pleuraler Tumoren. In: Ganten, D., Ruckpaul, K., Hahn, S.A., Schmiegel, W. (eds) Molekularmedizinische Grundlagen von nicht-hereditären Tumorerkrankungen. Molekulare Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56297-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-56297-6_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62572-5
Online ISBN: 978-3-642-56297-6
eBook Packages: Springer Book Archive